Posts by: Ana Pena, PhD

Ana Pena, PhD

Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.

February 19, 2020February 19, 2020

Real-world Use Supports Effectiveness of Advate, Adynovate, and Feiba, Takeda Data Show

News

Takeda presented new real-world data highlighting the underdiagnosis of hemophilia A and B, supporting the effectiveness and safety of its hemophilia therapies — Advate, Adynovate, and Feiba — and discussing potential benefits of ... Read more

February 10, 2020May 1, 2020

Catalyst Presents Positive Data of Under-the-Skin Candidate Therapies for Preventing, Treating Bleeds

News

Catalyst Biosciences has announced new clinical data supporting the safety and efficacy of its lead candidate therapies for treating hemophilia. Factor IX (FIX) dalcinonacog alfa (DalcA) was found to ... Read more

February 7, 2020February 14, 2020

MRI Superior to Radiography in Capturing Joint Changes That Signal Future Bleeds, Study Says

News

Joint changes detected by magnetic resonance imaging (MRI), and often are missed on radiographs, are a strong predictor of damaging bleeds over the next five years in joints of ... Read more

February 3, 2020February 3, 2020

First Child with Hemophilia B Dosed in Phase 4 Trial to Extend Ixinity to Those Under Age 12

News

Aptevo Therapeutics announced the dosing of a first patient in a Phase 4 study aiming to extend use of its prophylactic (preventive) treatment Ixinity (coagulation factor IX ) to ... Read more

January 27, 2020January 27, 2020

Prophylactic Use by Younger Patients Depends on Responsibility and Risk Estimates, Study Finds

News

The likelihood that teenagers and young adults with hemophilia will use a prophylactic replacement therapy as prescribed is mostly influenced by their level of responsibility in taking their infusions, and their own ... Read more

January 17, 2020January 17, 2020

Risk of Inhibitors with Nuwiq Similar to Plasma-derived Products in Untreated Hemophilia A Patients, Trial Shows

News

Adults and children with severe hemophilia A who are receiving Nuwiq (recombinant human coagulation factor VIII) as their first replacement therapy have a similar risk of developing inhibitors as ... Read more

December 20, 2019July 30, 2020

Takeda Presents Real-World Data on Cost-Effectiveness and Long-term Benefits of Adynovate and Feiba

News

Takeda has presented new real-world data to support the cost-effectiveness and persistent benefits to patients of its hemophilia A and B therapies: Adynovate and Feiba ... Read more

December 18, 2019December 18, 2019

Takeda Presents Early Data About Improving Efficiency of Hemophilia A and B Gene Therapy

News

Takeda has presented early data on the prevalence of — and a possible solution for — one of gene therapy’s main hurdles: the development of an immune reaction against the ... Read more

December 10, 2019December 13, 2019

New Early Data Support Catalyst’s MarzAA in Treating Acute Bleeds in Hemophilia

News

New preclinical data on one of Catalyst Biosciences‘ lead candidate therapies — marzeptacog alfa activated (MarzAA), an engineered clotting Factor VIIa (FVIIa) given as an under-the-skin injection — support its potential ... Read more

December 9, 2019December 18, 2019

Enzyre and Takeda to Develop Coagulation Test that Patients Can Use at Home

News

Enzyre is teaming up with Takeda to develop a diagnostic device that will allow people with hemophilia to determine their blood coagulation status at home. Under the collaboration agreement, ... Read more